Abstract
This study reports proof of concept for administering compacted DNA nanoparticles (DNPs) intracerebrally as a means to protect against neurotoxin-induced neurodegeneration of dopamine (DA) neurons. In this study we used DNPs that encoded for human glial cell line-derived neurotrophic factor (hGDNF); GDNF is a potent neurotrophic factor for DA neurons. Intracerebral injections of DNPs into the striatum and/or substantia nigra were performed 1 week before treatment with a neurotoxin. We observed that the number of surviving DA cells, the density of DA fiber terminals and recovery of motor function were greater in animals injected with GDNF-encoding DNPs than in control animals receiving DNPs encoding for an inert reporter gene. The results of these studies are one of the first to demonstrate that a non-viral, synthetic nanoparticle can be used to deliver therapeutic genes to cells in the brain as a means to protect cells against neurotoxin-induced neurodegeneration.
Original language | English |
---|---|
Pages (from-to) | 2209-2217 |
Number of pages | 9 |
Journal | Nanomedicine: Nanotechnology, Biology, and Medicine |
Volume | 13 |
Issue number | 7 |
DOIs | |
State | Published - Oct 2017 |
Bibliographical note
Funding Information:Funding: This research was supported in part by the National Institutes of Health R01 NS75871 (DMY) and S10 RR027463 (DMY).
Publisher Copyright:
© 2017 Elsevier Inc.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
Keywords
- Gene therapy
- Glial cell line-derived neurotrophic factor (GDNF)
- Lysine polymer
- Parkinson's disease
- Plasmid DNA
ASJC Scopus subject areas
- Bioengineering
- Medicine (miscellaneous)
- Molecular Medicine
- Biomedical Engineering
- Materials Science (all)
- Pharmaceutical Science